Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059522 · ClinicalTrials.gov registry record · Phase 3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
A Phase 3 study of Ovarian Cancer and Solid Tumors, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 20
- Study locations
NCT05059522 is a Phase 3 study of Ovarian Cancer and Solid Tumors that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 68 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05059522, a Phase 3 study of Ovarian Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Talazoparib
- DRUG Axitinib
- DRUG Avelumab
- DRUG Lorlatanib
Study Locations (20)
New York
- MSK Commack - Commack
- MSK Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). - New York
- Memorial Sloan Kettering Cancer Center 53rd street. - New York
- Memorial Sloan Kettering Cancer Center - New York
- MSK Nassau - Uniondale
Arkansas
- Highlands Oncology Group, PA - Fayetteville
- Highlands Oncology Group, PA - Rogers
- Highlands Oncology Group, PA - Springdale
New Jersey
- MSK Basking Ridge - Basking Ridge
- MSK Monmouth - Middletown
- MSK Bergen - Montvale
New South Wales
- Macquarie University - North Ryde
- Mater Hospital Sydney - Wollstonecraft
- Melanoma Institute Australia - Wollstonecraft
California
- UCLA Hematology/Oncology - Los Angeles
Florida
- Moffitt Cancer Center - Tampa
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05059522
The ClinicalTrials.gov registry entry for NCT05059522 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pemetrexed is the first listed.
NCT05059522 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Arkansas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05059522 about?
NCT05059522 is a clinical study titled "Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing". This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
What is the current status of trial NCT05059522?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2021-09-29. Estimated completion is 2026-09-30.
What conditions does trial NCT05059522 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumors, NSCLC, Urothelial Cancer, Advanced Malignancies.
What interventions are being tested in trial NCT05059522?
The interventions under investigation include: Pemetrexed (DRUG), Talazoparib (DRUG), Axitinib (DRUG), Avelumab (DRUG), Lorlatanib (DRUG).
Who is sponsoring clinical trial NCT05059522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05059522 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.